Stock Events

Stock Events

Pharnext 

€0.000000
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow P0X.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap31.91B
Biogen focuses on neurodegenerative diseases, directly competing with Pharnext's Charcot-Marie-Tooth disease treatment.
Alnylam Pharmaceuticals
ALNY
Mkt Cap41.76B
Alnylam Pharmaceuticals works on RNAi therapeutics for genetic diseases, overlapping with Pharnext's genetic disorder treatments.
Ionis Pharmaceuticals
IONS
Mkt Cap13.52B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, competing in the genetic disorder space.
Vertex Pharmaceuticals
VRTX
Mkt Cap134.02B
Vertex Pharmaceuticals engages in creating treatments for cystic fibrosis and other genetic disorders, competing with Pharnext's focus.
PTC Therapeutics
PTCT
Mkt Cap7.09B
PTC Therapeutics works on treatments for genetic disorders, directly competing with Pharnext's drug development focus.
Sarepta Therapeutics
SRPT
Mkt Cap2.04B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics, competing in the genetic and rare disease market.
CRISPR Therapeutics
CRSP
Mkt Cap5.92B
CRISPR Therapeutics is involved in gene editing, a technology that could compete with Pharnext's approach to treating genetic disorders.
Novartis
NVS
Mkt Cap305.1B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for neurological and genetic disorders, competing on multiple fronts with Pharnext.

About

Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of baclofen and acamprosate formulated as a pill for neurodegenerative diseases. The company was incorporated in 2007 and is headquartered in Suresnes, France.
Show more...
CEO
Mr. Daniel E. Cohen M.D., Ph.D.
Country
France
ISIN
FR0011191287

Listings

MU
DE
P0X.MU
STU
DE
P0X.STU

0 Comments

Share your thoughts

FAQ

What is Pharnext stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Pharnext stocks are traded under the ticker P0X.STU.
In which sector is Pharnext located?▼
Pharnext operates in the Health & Wellness sector.
When did Pharnext complete a stock split?▼
Pharnext has not had any recent stock splits.
Where is Pharnext headquartered?▼
Pharnext is headquartered in Suresnes, France.